氯胺酮与电休克治疗抑郁发作的疗效与安全性比较
该系统综述与Meta分析纳入6项临床试验共340例重性抑郁发作患者,比较氯胺酮与电休克治疗(ECT)的疗效与安全性。合并分析显示ECT在改善抑郁严重度方面优于氯胺酮(SMD=-0.69,95%CI -0.89至-0.48),认知/记忆及严重不良事件两组无显著差异,但两者不良事件谱不同。作者认为急性期ECT可能优于氯胺酮,治疗选择应个体化并以患者为中心。
要点
- ECT在急性期改善抑郁严重度可能优于氯胺酮(SMD=-0.69)。
- 认知/记忆表现与严重不良事件两组未见显著差异。
- 氯胺酮头痛与肌肉疼痛风险较低,ECT视力模糊、眩晕、复视/眼震及短暂分离症状风险较低。
核心结论
- 在重性抑郁发作急性期,ECT在改善抑郁严重度方面可能优于氯胺酮。
- 治疗选择应个体化并以患者为中心。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、MEDLINE、Cochrane Library和Embase,截至2022年4月19日,无语言限制。
- 纳入6项临床试验共340例患者(ECT组162例,氯胺酮组178例),其中5项为随机临床试验,6项均在住院环境开展。
主要发现
- 评估认知/记忆的研究及严重不良事件方面,两组间未观察到显著差异。
- 氯胺酮与ECT各有独特的不良事件谱:氯胺酮头痛和肌肉疼痛风险较低,ECT视力模糊、眩晕、复视/眼震及短暂分离/人格解体症状风险较低。
临床怎么用
- 对可接受ECT的重性抑郁发作住院患者,急性期可优先考虑ECT以更快改善抑郁严重度。
- 选择氯胺酮或ECT时应结合患者不良事件耐受性与偏好进行个体化决策。
局限性
- 纳入研究方法学质量为低至中等,且研究设计检验效能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Whether ketamine is as effective as electroconvulsive therapy (ECT) among patients with major depressive episode remains unknown. OBJECTIVE: To systematically review and meta-analyze data about clinical efficacy and safety for ketamine and ECT in patients with major depressive episode. DATA SOURCES: PubMed, MEDLINE, Cochrane Library, and Embase were systematically searched using Medical Subject Headings (MeSH) terms and text keywords from database inception through April 19, 2022, with no language limits. Two authors also manually and independently searched all relevant studies in US and European clinical trial registries and Google Scholar. STUDY SELECTION: Included were studies that involved (1) a diagnosis of depression using standardized diagnostic criteria, (2) intervention/comparator groups consisting of ECT and ketamine, and (3) depressive symptoms as an efficacy outcome using standardized measures. DATA EXTRACTION AND SYNTHESIS: Data extraction was completed independently by 2 extractors and cross-checked for errors. Hedges g standardized mean differences (SMDs) were used for improvement in depressive symptoms. SMDs with corresponding 95% CIs were estimated using fixed- or random-effects models. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was followed. MAIN OUTCOMES AND MEASURES: Efficacy outcomes included depression severity, cognition, and memory performance. Safety outcomes included serious adverse events (eg, suicide attempts and deaths) and other adverse events. RESULTS: Six clinical trials comprising 340 patients (n = 162 for ECT and n = 178 for ketamine) were included in the review. Six of 6 studies enrolled patients who were eligible to receive ECT, 6 studies were conducted in inpatient settings, and 5 studies were randomized clinical trials. The overall pooled SMD for depression symptoms for ECT when compared with ketamine was -0.69 (95% CI, -0.89 to -0.48; Cochran Q, P = .15; I2 = 39%), suggesting an efficacy advantage for ECT compared with ketamine for depression severity. Significant differences were not observed between groups for studies that assessed cognition/memory or serious adverse events. Both ketamine and ECT had unique adverse effect profiles (ie, ketamine: lower risks for headache and muscle pain; ECT: lower risks for blurred vision, vertigo, diplopia/nystagmus, and transient dissociative/depersonalization symptoms). Limitations included low to moderate methodological quality and underpowered study designs. CONCLUSIONS AND RELEVANCE: Findings from this systematic review and meta-analysis suggest that ECT may be superior to ketamine for improving depression severity in the acute phase, but treatment options should be individualized and patient-centered.
引用
- Rhee TG, Shim SR, Forester BP, et al. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022. PMID: 36260324. doi:10.1001/jamapsychiatry.2022.3352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。